The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
Merck & Co. announced that the U.S. Food and Drug Administration accepted for review supplemental New Drug Applications (sNDAs) for Pifeltro and Delstrigo.
Yale Researchers Discover Immune System Protein That Can Help Suppress HIV
Apobec3A (A3A) protein, Cells, FDA, Gene Expression, HIV, Immune System, Lupus nephritis, Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), R&D, T-Cells, U.S. Centers for Disease Control and Prevention, Viral Genes, VirusesA new report released by researchers at Yale University could change the way some HIV patients are treated.
An experimental HIV immunotherapy treatment is showing significant promise in clinical testing. A study shows the two-drug combination is capable of suppressing HIV for months at a time.
HIV-positive patients may soon have a new treatment option that can be taken without food restrictions and has a much lower rate of drug interference with other medications patients may be taking.